Septodont is pleased to announce the successful completion of its acquisition of a 51% interest in Inibsa. This operation follows the receipt of customary regulatory approvals and satisfaction of closing conditions.
In this strategic transaction, Septodont has acquired a controlling stake in Inibsa, alongside Acteon, a Dentressangle portfolio company, as a strong partner and non-controlling shareholder. This acquisition represents another significant milestone in Septodont’s long-term growth strategy.
Olivier SCHILLERChairman of the board
“ This acquisition of control of Inibsa will expand Septodont’s development in dental products and help us further strengthen our geographical footprint. This is an important acquisition for us that will provide compelling value creation and accelerated growth opportunities given the complementary nature of our assets and teams. ”
Inibsa is a global pharmaceutical group located in Spain specializing in the production of injectable anesthetics and in the distribution of a large portfolio of dental products.
junho 30th, 2025
